Cardiovascular Events after Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Key Points

• Cardiovascular events significantly increase after allogeneic hematopoietic cell transplantation, impacting patient survival.
• Among the observed cases, a notable 30% developed cardiac complications in the first year post-transplantation.
• Assessment of transplant records indicates that post-transplant cyclophosphamide may influence cardiovascular risk.
• These findings underline the importance of ongoing heart health assessments in transplant recipients.